Clinical Trial

A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

Study acronym: PULSE
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-11-17; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2025-12-23
Trial Details
NCT Number NCT07241104
Lead Sponsor AstraZeneca
Conditions Dilated Cardiomyopathy
Enrollment 31 participants
Start Date 2025-12-01
Primary Completion 2027-11-22 (estimated)
Study Completion 2027-11-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-16